Anzeige
Mehr »
Login
Samstag, 23.11.2024 Börsentäglich über 12.000 News von 677 internationalen Medien
Microsofts, Googles und Amazons nukleares Wettrennen macht diese Uranaktie zu einem Muss!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
354 Leser
Artikel bewerten:
(0)

Elsevier Collaborates With M*Modal to Launch Next-Generation Diagnostic Decision Support Workflow

Finanznachrichten News

PHILADELPHIA, July 21, 2018 /PRNewswire/ -- Integrated speech reporting and diagnostic decision support workflow to be demonstrated at AHRA 2018

Elsevier, the global information analytics business specializing in science and health, and part of RELX Group, announced today that it has entered into an agreement to offer its STATdx online radiology diagnostic decision support tool through M*Modal Fluency for Imaging, an advanced speech recognition and workflow management system, to deliver the next generation of diagnostic decision support. This combined solution will be demonstrated during the Association of Medical Imaging Management (AHRA) 2018 annual meeting in Orlando from July 22-25.

STATdx, written by renowned radiologists in each specialty and widely regarded as the "gold standard" of radiology reference solutions, increases accuracy and confidence in diagnosing complex imaging cases and includes more than 4,000 common and complex diagnoses, 200,000 expert-selected and annotated image examples, 20,000 easily sortable patient cases with cine clips for select topics and much more.

Elsevier's STATdx received two prestigious awards in 2017. STATdx received Frost & Sullivan's 2017 North America Technology Innovation Award. STATdx also received top honors in the Digital and Online Resources category at the British Medical Association's awards.

"The STATdx integration with M*Modal will expedite the diagnostic process by putting together two critical tools in one place, streamlining the workflow," said Hajo Oltmanns, Senior Vice President and Chief Commercial Officer, Clinical Solutions, Elsevier. "Radiologists' reports will not only be more accurate, but this integrated solution will provide completeness, conformity, usability and consistency to drive actions and deliver value to the healthcare provider and, ultimately, the patient."

Currently, medical knowledge is growing at such a rapid pace that clinicians cannot keep up. Reliable information sources are not easily accessible, and healthcare providers must rely on limited sets of information to determine diagnoses. Also, the content from clinician notes is not always in the correct context, which can cause confusion and errors in decision-making. This situation can be resolved by deep workflow integration with intelligent search that connects radiologists with content in the appropriate context to make quicker, more confident diagnosis.

Chris Spring, Vice President Imaging Solutions at M*Modal, added, "The goal of this combined solution is to drive significantly better detection, interpretation and classification of disease so that clinicians can make the most appropriate diagnoses."

To see a demonstration of this solution, please stop by the M*Modal booth (# 1306) at AHRA July 22-25.

About M*Modal
M*Modal is a leading healthcare technology provider of advanced clinical documentation solutions, enabling hospitals and physicians to enrich the content of patient electronic health records (EHR) for improved healthcare and comprehensive billing integrity. As one of the largest clinical transcription service providers in the U.S., with a global network of medical editors, M*Modal also provides advanced cloud-based Speech Understanding technology and data analytics that enable physicians and clinicians to include the context of their patient narratives into electronic health records in a single step, further enhancing their productivity and the cost-saving efficiency and quality of patient care at the point of care. For more information, please visit www.mmodal.com, Twitter, Facebook and YouTube.

About Elsevier
Elsevier is a global information analytics business that helps institutions and professionals advance healthcare, open science and improve performance for the benefit of humanity. Elsevier provides digital solutions and tools in the areas of strategic research management, R&D performance, clinical decision support and professional education, including ScienceDirect, Scopus, SciVal, ClinicalKey and Sherpath. Elsevier publishes over 2,500 digitized journals, including The Lancet and Cell, 38,000 e-book titles and many iconic reference works, including Gray's Anatomy. Elsevier is part of RELX Group, a global provider of information and analytics for professionals and business customers across industries. www.elsevier.com

Media contact
Christopher Capot
Global Communications
Elsevier
+1-917-704-5174
c.capot@elsevier.com

© 2018 PR Newswire
Treibt Nvidias KI-Boom den Uranpreis?
In einer Welt, in der künstliche Intelligenz zunehmend zum Treiber technologischer Fortschritte wird, rückt auch der Energiebedarf, der für den Betrieb und die Weiterentwicklung von KI-Systemen erforderlich ist, in den Fokus.

Nvidia, ein Vorreiter auf dem Gebiet der KI, steht im Zentrum dieser Entwicklung. Mit steigender Nachfrage nach leistungsfähigeren KI-Anwendungen steigt auch der Bedarf an Energie. Uran, als Schlüsselkomponente für die Energiegewinnung in Kernkraftwerken, könnte dadurch einen neuen Stellenwert erhalten.

Dieser kostenlose Report beleuchtet, wie der KI-Boom potenziell den Uranmarkt beeinflusst und stellt drei aussichtsreiche Unternehmen vor, die von diesen Entwicklungen profitieren könnten und echtes Rallyepotenzial besitzen

Handeln Sie Jetzt!

Fordern Sie jetzt den brandneuen Spezialreport an und profitieren Sie von der steigenden Nachfrage, der den Uranpreis auf neue Höchststände treiben könnte.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.